Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
120
Participants
Timeline
Start Date
June 27, 2025
Primary Completion Date
October 31, 2026
Study Completion Date
January 19, 2027
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
DRUG
HSK44459
HSK44459
All Listed Sponsors
lead
Haisco Pharmaceutical Group Co., Ltd.
INDUSTRY
NCT07019090 - Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter | Biotech Hunter